[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.202.44. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
October 1983

Total, Dialyzable, and Nondialyzable Postabsorptive Hydroxyproline: Values in Patients With Cancer

Author Affiliations

From the Departments of Internal Medicine (Drs Niell, Palmieri, Neely, and Maxwell) and Urology (Drs Hopkins and Soloway), University of Tennessee Center for the Health Sciences, and the Hematology/Oncology Section, Veterans Administration Medical Center (Drs Niell and Maxwell), Memphis.

Arch Intern Med. 1983;143(10):1925-1927. doi:10.1001/archinte.1983.00350100097020
Abstract

• The postabsorptive urinary total (T), dialyzable (D), and nondialyzable (ND) hydroxyproline (HYPRO) tests were evaluated to determine whether the patterns of excretion varied according to the predominance of osteoblastic v osteolytic bone involvement in 58 patients with neoplastic disease. In patients with osteolytic lesions from multiple myeloma, elevated T and D levels with normal ND HYPRO values were observed, along with elevated D/ND ratios. In prostate cancer, the T, D, and ND values were all elevated and the D/ND ratio was normal. Patients with Hodgkin's disease had elevated T, D, and ND HYPRO levels, and the D/ND ratio was in the range of patients with prostate cancer. The data suggest that these collagen markers may be useful in the long-term evaluation of these neoplasms in patients.

(Arch Intern Med 1983;143:1925-1927)

×